Dumont Bénédicte, Minullina Izida, Loyau Stéphane, Monteiro Renato C, Lacapere Jean-Jacques, Arocas Véronique, Jandrot-Perrus Martine
Institut National de la Santé et de la Recherche Médicale, INSERM, U698, Université Paris 7, Hôpital Bichat, France.
J Mol Biol. 2006 Sep 1;361(5):877-87. doi: 10.1016/j.jmb.2006.06.053. Epub 2006 Jul 7.
Glycoprotein (GP) VI, a key receptor for collagen-induced platelet activation, recently emerged as a major target for developing new antithrombotics. However, little is known about its functional domains, which is a disadvantage for the rational development of antagonists. Our aim was to identify the structures determining GPVI specificity. GPVI presents homologies with members of the Ig superfamily (in particular with FcalphaRI) whose extracellular parts present two domains, D1 and D2 linked by a hinge interdomain. To identify the respective role of these domains in GPVI, we have substituted D1 and D2 by their FcalphaRI homologue in a soluble GPVI fusion protein (GPVI-Fc) and have modified the linker motif by mutagenesis. Proteins were tested for their binding to ligands and antibodies specific for GPVI and FcalphaRI. We demonstrate for the first time that D2 plays a specific and significant role in GPVI binding to collagen and that the hinge interdomain is critical for the binding to convulxin. Furthermore, binding to CRP requires elements of D1 and of the linker motif. Our results indicate that GPVI is unique amongst the receptors of its family as it uses different structural domains to interact with several agonists and provide evidence that different sites on GPVI constitute targets to develop antagonists of GPVI.
糖蛋白(GP)VI是胶原蛋白诱导的血小板活化的关键受体,最近成为开发新型抗血栓药物的主要靶点。然而,对其功能结构域了解甚少,这不利于合理开发拮抗剂。我们的目的是确定决定GPVI特异性的结构。GPVI与免疫球蛋白超家族成员(特别是与FcalphaRI)具有同源性,其细胞外部分有两个结构域,D1和D2通过一个铰链结构域相连。为了确定这些结构域在GPVI中的各自作用,我们在可溶性GPVI融合蛋白(GPVI-Fc)中用其FcalphaRI同源物替换了D1和D2,并通过诱变修饰了连接基序。测试了蛋白质与GPVI和FcalphaRI特异性配体及抗体的结合情况。我们首次证明D2在GPVI与胶原蛋白的结合中起特定且重要的作用,并且铰链结构域对于与芋螺毒素的结合至关重要。此外,与CRP的结合需要D1和连接基序的元件。我们的结果表明,GPVI在其家族受体中是独特的,因为它利用不同的结构域与多种激动剂相互作用,并提供了证据表明GPVI上的不同位点构成了开发GPVI拮抗剂的靶点。